title: Clinical study on effect of Astragalus Injection and its immuno-regulation action in treating chronic aplastic anemia.
abstract: OBJECTIVE
  To observe the clinical effect of Astragalus Injection (, AI) and its immuno-regulatory action in treating chronic aplastic anemia (CAA).
  
  
  METHODS
  Sixty patients with CAA were randomly assigned to two groups equally, both were treated with Stanozolol three times a day, 2 mg each time through oral intake, but AI was given additionally to the patients in the treated group once a day via intravenous dripping. All were treated for 15 days as one therapeutic course and the whole medication lasted for more than 4 months totally, with follow-up adopted. The clinical efficacy was estimated and the changes of T-lymphocyte subsets in peripheral blood as well as the serum levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-2 (IL-2) were observed.
  
  
  RESULTS
  The total effective rate in the treated group was 83.3% (25/30), which was higher than that in the control group 66.7% (20/30), showing significant difference between them (P<0.05). Levels of hemoglobin, WBC, reticular cell and platelet were elevated in both groups after treatment, but the improvement was significantly better in the treated group than that in the control group with respect to the former three indexes (P<0.05). The level of CD4(+) increased and that of CD8(+) decreased significantly after treatment in the treated group (P<0.05), which showed significant difference as compared with those in the control group (P<0.05). Levels of serum TNF-alpha and IL-2 lowered after treatment in both groups, but significance only showed in the treated group (P<0.05). The degree of proliferation in bone marrow got raised significantly and the percentage of non-hemopoietic cells reduced significantly in the treated group after treatment, also showing significant difference to those in the control group (P<0.05).
  
  
  CONCLUSIONS
  AI could promote the recovery of hemopoietic function, which might be through improving T-lymphocyte subsets and reducing the release of negative regulatory factors such as TNF-alpha and IL-2 to alleviate the inhibition on hemopoietic function.
authors.affiliation: TCM Hospital of Langfang City, Chinese Hemopathic Therapeutic Center of TCM, Hebei, 065000, China. wms65352003@163.com
authors.forename: Mao-sheng
authors.initials: MS
authors.lastname: Wang
authors.forename: Jun
authors.initials: J
authors.lastname: Li
authors.forename: Hai-xia
authors.initials: HX
authors.lastname: Di
authors.forename: Zhen-li
authors.initials: ZL
authors.lastname: Li
authors.forename: Shu-Lian
authors.initials: SL
authors.lastname: Yang
authors.forename: Wei
authors.initials: W
authors.lastname: Hou
authors.forename: Jin-yu
authors.initials: JY
authors.lastname: Yan
authors.forename: Xiao-min
authors.initials: XM
authors.lastname: Zhao
mesh_terms: D000741:Anemia, Aplastic / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D027883:Astragalus Plant; D001853:Bone Marrow / Q000187:drug effects; D002908:Chronic Disease; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D007376:Interleukin-2 / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D004365:Drugs, Chinese Herbal; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha